This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-21. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
== Research directions == Research into the mechanism of HD is focused on identifying the functioning of Htt, how mHtt differs or interferes with it, and the brain pathology that the disease produces. Research is conducted using in vitro methods, genetically modified animals, (also called transgenic animal models), and human volunteers. Animal models are critical for understanding the fundamental mechanisms causing the disease, and for supporting the early stages of drug development. The identification of the causative gene has enabled the development of many genetically modified organisms including nematodes (roundworms), Drosophila fruit flies, and genetically modified mammals including mice, rats, sheep, pigs and monkeys that express mutant huntingtin and develop progressive neurodegeneration and HD-like symptoms. Research is being conducted using many approaches to either prevent HD or slow its progression. Disease-modifying strategies can be broadly grouped into three categories: reducing the level of the mutant huntingtin protein (including gene splicing and gene silencing); approaches aimed at improving neuronal survival by reducing the harm caused by the protein to specific cellular pathways and mechanisms (including protein homeostasis and histone deacetylase inhibition); and strategies to replace lost neurons. In addition, novel therapies to improve brain functioning are under development; these seek to produce symptomatic rather than disease-modifying therapies, and include phosphodiesterase inhibitors.
After a Spanish reconquest, Colombian independence was secured and the Gran Colombia period began in 1819. The new polity experimented with federalism as the Granadine Confederation (1858) and then the United States of Colombia (1863), before becoming a centralised republic in 1886. With the backing of the US and France, Panama seceded from Colombia in 1903, resulting in Colombia's present borders. Beginning in the 1960s, the country has suffered from an asymmetric low-intensity armed conflict and political violence, both of which escalated in the 1990s. Since 2000, there has been improvement in security, stability, and rule of law, as well as economic growth and development. Colombia is recognized for its healthcare system, being the best healthcare in the Americas according to the World Health Organization and 22nd in the world. Its diversified economy is the third-largest in South America, with macroeconomic stability and favorable long-term growth prospects. The country has one of the widest recognitions of LGBT rights, gender equality, animal rights, and human rights, permitting same-sex adoption, same-sex marriage, legality of abortion, legality of euthanasia, and animal rights protections. Colombia is one of the world's seventeen megadiverse countries; it has the highest level of biodiversity per square mile in the world, and second-highest level overall. Its territory encompasses the Amazon rainforest, highlands, grasslands and deserts.
Yukimi Todo (藤堂 雪見, Tōdō Yukimi) Voiced by: Yu Miyazaki (Japanese); Aiden Call (English) Member of the Town of Winter's elite security. He's a kind and caring agent who guards Hinagiku and Sakura on Rousei and Itechou's orders. He monitored Rousei and Hinagiku's relationship during the month of the Summoning of the Four Seasons. Rintaro Shimotsuki (霜月 倫太郎, Shimotsuki Rintarō) Voiced by: Hayato Kashiwazaki (Japanese); Mauricio Ortiz-Segura (English) Member of the Town of Winter's elite security. Along with Todo, he guards the two girls on Rousei and Itechou's orders. He holds Itechou in high regard.
Sources: en.wikipedia.org
Battle for the Mariana Islands on YouTube Order of battle WW2DB: The Marianas and the Great Turkey Shoot Battle of the Philippine Sea at Combinedfleet.com Animated History of The Battle of the Philippine Sea The Controversy over Spruance's Decision Air Group 31's participation in the Battle of the Philippine Sea A Brief Account of the Battle
=== Good gasoline yields === There are three types of crude oil, light, medium and heavy, according to its density. For gasoline blends, composites which are lighter hydrocarbons are used. Molecular weights of these hydrocarbons are lower than heptane. Since most of Nigerian crudes are either light or medium sweet, creating plentiful amount of diesel, they are more costly than sour crudes. Gasoline is produced from processed crude oil and it is highly valued petroleum products. Therefore, to have maximized profit, refiners seek to boost gasoline yields.
=== Surface of the Moon === In 2009, India's Chandrayaan-1 satellite and the National Aeronautics and Space Administration (NASA) Cassini spacecraft and Deep Impact probe each detected evidence of water by evidence of hydroxyl fragments on the Moon. As reported by Richard Kerr, "A spectrometer [the Moon Mineralogy Mapper, also known as "M3"] detected an infrared absorption at a wavelength of 3.0 micrometers that only water or hydroxyl—a hydrogen and an oxygen bound together—could have created." NASA also reported in 2009 that the LCROSS probe revealed an ultraviolet emission spectrum consistent with hydroxyl presence. On 26 October 2020, NASA reported definitive evidence of water on the sunlit surface of the Moon, in the vicinity of the Clavius crater, obtained by the Stratospheric Observatory for Infrared Astronomy (SOFIA). The SOFIA Faint Object infrared Camera for the SOFIA Telescope (FORCAST) detected emission bands at a wavelength of 6.1 micrometers that are present in water but not in hydroxyl. The abundance of water on the Moon's surface was inferred to be equivalent to the contents of a 12-ounce bottle of water per cubic meter of lunar soil. The Chang'e 5 probe, which landed on the Moon on 1 December 2020, carried a mineralogical spectrometer that could measure infrared reflectance spectra of lunar rock and regolith. The reflectance spectrum of a rock sample at a wavelength of 2.85 micrometers indicated localized water/hydroxyl concentrations as high as 180 parts per million.
Sources: en.wikipedia.org
=== North America === In North America, medical physics training is offered at the master's, doctorate, post-doctorate and/or residency levels. A professional doctorate has also been recently introduced as an option. Several universities in Canada and the United States offer these degrees. As of October 2013, over 70 universities in North America have medical physics graduate programs or residencies that are accredited by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP). The majority of residencies are therapy, but diagnostic and nuclear have also been on the rise in the past several years. In the United States, professional certification is obtained from the American Board of Radiology (for all 4 areas) the American Board of Medical Physics (for MRI), the American Board of Science in Nuclear Medicine (for Nuc Med and PET). As of 2012, enrollment in a CAMPEP-accredited residency or graduate program is required to start the ABR certification process. As of 2013, completion of a CAMPEP-accredited residency is required to advance to part 2 of the ABR certification process. In Canada, professional certification is obtained from the Canadian College of Physicists in Medicine (for all 4 areas and Mammography). Since 2016, eligibility requirements for Radiation Oncology Physics certification includes graduation and post-graduate training from a CAMPEP accredited institution.
== Production == Bulk carbon-13 for commercial use, e.g. in chemical synthesis, is enriched from its natural 1.1% abundance. Carbon-13 can be separated from the major carbon-12 isotope via techniques such as thermal diffusion, chemical exchange, gas diffusion, laser, cryogenic distillation, or chemical exchange of CO2 , however, only cryogenic distillation of methane (boiling point −161.5 °C) or carbon monoxide (b.p. −191.5 °C) is economically feasible for industrial production as of 2010. Industrial carbon-13 production plants represent a substantial investment: greater than 100-meter-tall (330 ft) cryogenic distillation columns are needed to separate the carbon-12 or carbon-13 containing compounds. The largest reported commercial carbon-13 production plant in the world as of 2014 has an annual production capability of ~400 kg of carbon-13. In contrast, a 1969 carbon monoxide cryogenic distillation pilot plant at Los Alamos Scientific Laboratories could produce 4 kg of carbon-13 annually.
== Adverse effects == Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain. Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.